Clinical Trial Goal
To find out:
- The highest dose of niclosamide that’s safe to give with cytarabine
- If the combination of cytarabine and niclosamide is safe and works well to treat AML that has relapsed or is refractory in children and young adults
You may be able to join this trial if you:
Your child:
- Is 2 - 25 years old
- Has AML that has relapsed or is refractory
- Does not have acute promyelocytic leukemia
- Does not have graft-versus-host-disease (GVHD)
- You agree to have other standard tests done to see if your child can be in the clinical trial
Trial Details
Cytarabine is a chemotherapy (chemo) drug that blocks the growth of cancer cells.
Niclosamide is an antihelminthic drug that is used to treat parasitic infections.
Your child will get:
Niclosamide is an antihelminthic drug that is used to treat parasitic infections.
Your child will get:
- Cytarabine – Given as intravenous (IV) infusions. The dose your child will get depends on when they start the trial and how safe it has been
- Niclosamide – A pill that your child takes by mouth 2 times each day for 14 days
Your child will have biopsies to see how well the treatment is working. The clinical trial doctors will check your child's health for up to 2 months.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat AML that has relapsed or is refractory in children and young adults is new and unproven.
Locations
Stanford UniversityRECRUITING
Palo Alto, California
Nancy Sweeters, RN, PNP, 650-721-4074, nks2016@stanford.edu
Sponsors
collaborator: The Leukemia and Lymphoma Society, collaborator: Pediatric Cancer Research Foundation (PCRF), collaborator: CURE Childhood Cancer, Inc., lead: Stanford University
